DMT Frog vs Kambo Frog: Why They Are Not the Same

Two amphibians get called "medicine" online, and people searching for the dmt frog routinely land on pages about the other one. The first is a desert toad from Arizona and Sonora whose glands contain 5-MeO-DMT. The second is a tree frog from the Amazon whose skin secretion contains peptides and no psychedelic tryptamine at all. They are different animals, different molecules, different risks, and different legal questions.

Our dmt frog species reference covers the toad in depth. This article puts the two side by side, because the confusion between them is not harmless.

What people mean by "DMT frog"

The animal behind the search is not a frog and it does not make DMT. It is Incilius alvarius, the Colorado River toad or Sonoran Desert toad, described in 1859 under the older name Bufo alvarius and renamed more than once since. It is a true toad in the family Bufonidae, which technically sits inside the frogs, but the parotoid glands behind its eyes are a toad feature that no tree frog has.

Those glands produce a defensive secretion containing 5-MeO-DMT and bufotenine. Neither is N,N-DMT. The secretion also carries bufadienolides, cardioactive steroids that act on the heart in a way comparable to digoxin. Smoking dried secretion is the practice people are talking about; licking the animal is the dangerous myth. Swallowing toad toxin has caused documented poisonings.

The practice of smoking the secretion traces to a self-published pamphlet from 1983, not to an ancient tradition. New Mexico lists the toad as threatened under state law, and demand for its secretion is a modern pressure on a wild population. Every registered clinical trial of 5-MeO-DMT uses the synthetic compound rather than anything collected from an animal.

What the kambo frog actually is

Kambo comes from Phyllomedusa bicolor, often called the giant monkey frog or giant leaf frog. It is a large green tree frog of the Amazon basin, with smooth moist skin and long limbs built for climbing. It has no parotoid glands and produces no 5-MeO-DMT, no bufotenine, and no DMT.

Its skin secretion is a cocktail of bioactive peptides rather than small tryptamine molecules. Several of them, including dermorphin and deltorphin, act on opioid receptors. Others affect blood vessels, smooth muscle, and the gut. The secretion is traditionally collected by scraping it from the frog onto sticks and drying it, then rehydrated and applied to small superficial burns on the skin.

The experience is not a psychedelic one in the sense people associate with 5-MeO-DMT. Within minutes the peptides enter the bloodstream and produce flushing, a racing heart, swelling of the face, a drop in blood pressure, and intense vomiting. The whole episode typically passes in well under an hour. Practitioners describe it as a purge, and the pharmacology supports that description more than any claim about visions.

Unlike the toad, the kambo frog does have a documented history of Indigenous use among Amazonian peoples, who apply it before hunting. That history is real, but it is a cultural fact rather than a safety clearance. The animal is not generally harvested to death, since the secretion is scraped and the frog released, though the welfare of handling and stressing wild frogs is its own debate.

Why mixing up the DMT frog and kambo is a safety issue

The two substances fail in different ways, so advice that is correct for one can be wrong for the other.

With toad secretion the central hazards are cardiac and dose-related. Wild secretion is not a standardized product. Nobody collecting it in the field knows the 5-MeO-DMT concentration, so nobody smoking it knows the dose. Bufadienolides are present in raw secretion and absent in a synthetic, assayed compound.

The serious drug interactions sit on the serotonin side: monoamine oxidase inhibitors, lithium, and a personal history of psychosis are treated as absolute exclusions in our 5-MeO-DMT therapy screening, and SSRIs and SNRIs call for a supervised taper plan.

With kambo the hazards look nothing like that. The documented harms involve the purge itself. Case reports describe dangerously low blood sodium after people drank large volumes of water before the session and then vomited repeatedly, along with reports of cardiac events and deaths associated with the practice. Opioid-receptor peptides raise a separate question for anyone currently on, or recently off, opioids or opioid-blocking medication.

There is no cardiac screening culture around kambo the way there is beginning to be around 5-MeO-DMT, because most kambo is administered outside any medical setting.

A person who read a toad safety page and then books a kambo circle has prepared for the wrong set of risks. The reverse is also true. Someone who was told kambo is "just a cleanse" and then smokes toad secretion has no idea that a measured-in-milligrams psychedelic with a cardiac co-toxin is a completely different event.

Part of the confusion is vocabulary. Both practices are sold with the same words: medicine, ceremony, purge, cleanse, reset. Both are often offered by the same facilitators, sometimes on consecutive days, and both appear in the same social media feeds under the same hashtags. The shared language suggests a shared category, and there is none.

One is a serotonergic psychedelic with a cardiac co-toxin from a desert toad. The other is a peptide purgative from a rainforest frog. The only thing they genuinely have in common is that both come from an amphibian's skin.

The practical consequence for anyone with a medical history is that the intake questions differ. For 5-MeO-DMT the questions that matter are about antidepressants, lithium, psychiatric history, and heart rhythm. For kambo they are about opioids, blood pressure, kidney function, and how much water you intend to drink. A facilitator who asks the same three questions for both is not screening for either.

How the law treats each one

5-MeO-DMT is a Schedule I controlled substance in the United States with its own DEA drug code, separate from DMT and separate from bufotenine. Collecting toad secretion therefore means possessing a Schedule I substance regardless of what the animal's conservation status says. The toad itself is protected under state law in New Mexico and is presumed gone from California.

Kambo is not a scheduled substance under United States federal law. That is the fact behind most of the confident marketing around it. Being unscheduled is not the same as being approved, evaluated, or regulated, and some jurisdictions have moved against it. Australia's medicines regulator placed kambo in its prohibited schedule in 2021.

In most of the world the practice exists in a gray zone where a practitioner's training, if any, is self-declared.

For a reader trying to make a decision, the legal distinction cuts both ways. The toad compound is restricted because it is a potent psychoactive drug, which is also why there is a growing body of registered research on its synthetic form. Kambo escapes scheduling partly because it is not psychoactive in that sense, which also means almost nobody is studying it under controlled conditions.

Does either one belong in a medical program?

Our programs are built around ibogaine and synthetic 5-MeO-DMT, and kambo is not one of them. The reasoning follows from everything above. A compound can be included in a physician-supervised protocol when its dose can be measured, its interactions are mapped, and its cardiac effects can be monitored in real time. Synthetic 5-MeO-DMT meets that bar: the dose is known in milligrams, the bufadienolides are simply absent, and no toad is collected.

Toad secretion does not meet it, for the dose-uncertainty and co-toxin reasons already described. Kambo does not meet it either, for a different reason: it is a mixture of peptides with opioid and vasoactive effects, administered through skin burns, with a harm profile that is documented mainly in case reports rather than in controlled studies. Dose control, interaction mapping, and monitoring are the three tests, and only the synthetic compound passes all three.

Where 5-MeO-DMT does appear in a program, sequencing matters. The ibogaine 5-MeO-DMT combination used at MindScape places the 5-MeO-DMT session after the ibogaine work and after the cardiac recovery window, with its own screening, its own electrocardiogram review, and its own integration period. None of that is improvised, and none of it involves an animal.

Questions to ask if you are still weighing both

If you are comparing the dmt frog with kambo because someone offered you one of them, these questions sort the serious providers from the rest.

1. Which animal, and which molecule, are we actually talking about? A provider who cannot answer this clearly is not someone to trust with your heart rhythm.
2. Is the substance synthetic and assayed, or collected from a wild animal? For 5-MeO-DMT this determines whether the dose is known. For kambo the answer is always wild-collected.
3. What medical screening happens before the session, and who performs it? Look for a physician, an electrocardiogram, a medication review, and a mental health history for 5-MeO-DMT. Be skeptical of any kambo setting that asks nothing about opioids, blood pressure, or fluid intake.
4. What is the emergency plan? Where is the nearest hospital, who is trained, and what equipment is on site?
5. What happens afterward? Integration support, follow-up contact, and a plan for the weeks after are what separate treatment from an event.

The toad and the frog share a reputation and almost nothing else. If what brought you here is interest in a measured, supervised 5-MeO-DMT session as part of a broader recovery plan, the next step is a confidential medical pre-screen with MindScape Retreat, where a physician reviews your medications, your cardiac history, and whether the dmt frog question even applies to the treatment you are considering.

This article is educational and is not medical advice. If you are in crisis in the United States, call or text 988.